Skip to main content
Press Release

Dedham Veterinarian Agrees to Pay $15,000 Settlement to Resolve Allegations of Inadequate Recordkeeping of Controlled Substances

For Immediate Release
U.S. Attorney's Office, District of Massachusetts

BOSTON – A Dedham veterinarian has agreed to resolve allegations that he maintained inadequate records of controlled substances, improperly stored controlled substances at his office and residence, ordered controlled substances without a Drug Enforcement Administration (DEA) registration, and failed to report he was on probation on his DEA registration forms.

Wilbur M. Salter, II D.V.M., a veterinarian who practices at Animed Pet Hospital in Dedham, has agreed to pay $15,000 to resolve allegations that he violated the civil remedies provisions of the Controlled Substances Act (CSA). The CSA was enacted to prevent the diversion or misuse of controlled substances and requires complete and accurate recordkeeping by medical professionals—including veterinarians—and others involved in the distribution and administration of controlled substances.

According to the settlement agreement, Dr. Salter admitted that he did not furnish required records with respect to Euthanasia Solution, Ketamine, Diazepam 5mg, Hydrocodone liquid, and Diazepam 1mg in connection with a 2019 DEA audit of controlled substances at his practice. As a result, the investigators found CSA violations with respect to these controlled substances. Dr. Salter also admitted that he stored controlled substances at his residence, but did not register his residence with the DEA; improperly stored Tramadol, a controlled substance, in an unlocked cabinet; ordered a schedule IV controlled substance after he no longer held a DEA registration; and did not report that the Board of Registration in Veterinary Medicine had placed him on probation on his subsequent DEA registration forms, as required. 

“It is essential that all prescribers—including veterinarians—keep accurate records of controlled substances so that we can identify and prevent any diversion, especially in the midst of a rampant and destructive opioid epidemic,” said United States Attorney Rachael S. Rollins. “We will enforce compliance of these important safeguards.”   

“The DEA is committed to ensuring that all registrants are in compliance with the required regulations, which are enforceable through the Controlled Substances Act,” said Brian D. Boyle, Special Agent in Charge of the DEA, Boston Division. “Failure to do so increases the potential for diversion and jeopardizes public health and public safety. DEA pledges to work with our law enforcement and regulatory partners to ensure these rules and regulations are followed.”

During the investigation, Dr. Salter surrendered his DEA registration number and, as part of the settlement, agreed that he would not seek a new DEA registration number.

U.S Attorney Rollins and DEA SAC Boyle made the announcement today. Assistant U.S. Attorney Carol E. Head of Rollins’ Civil Division handled the case.

Updated September 21, 2022

Prescription Drugs